AstraZeneca, Author Interviews, Boehringer Ingelheim, Diabetes, Eli Lilly, J&J-Janssen, Merck, Pharmacology / 18.10.2017
Oral Semaglutide As Effective As Injectable In Reducing A1C and Weight Loss
MedicalResearch.com Interview with:
Melanie J Davies CBE MB ChB MD FRCP FRCGP
Professor of Diabetes Medicine
NIHR Senior Investigator Emeritus
Diabetes Research Centre
Leicester Diabetes Centre – Bloom
University of Leicester
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This was the first study to test the effectiveness of an oral GLP-1 in patients with type 2 diabetes.
The main findings were that compared to both placebo and a GLP-1, Semaglutide, delivered by sub-cutaneous injection weekly, the oral therapy delivered once a day produced better results than placebo and similar results to injectable GLP-1 with regard to reductions in HbA1c and weight loss.
(more…)